{"id": "article-23033_0", "title": "Human Papilloma Virus Vaccine -- Continuing Education Activity", "content": "The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58.\u00a0HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization.", "contents": "Human Papilloma Virus Vaccine -- Continuing Education Activity. The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58.\u00a0HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization."}
{"id": "article-23033_1", "title": "Human Papilloma Virus Vaccine -- Continuing Education Activity", "content": "The exact mechanism of action of 9vHPV\u00a0remains unclear, as\u00a0HPV only affects humans, which poses challenges for research. However, researchers hypothesize that the vaccine operates by triggering the humoral response. This activity comprehensively examines the indications, actions, and contraindications of the 9vHPV vaccine as a crucial tool in managing and preventing HPV infection and associated diseases. Furthermore, this activity underscores the mechanism of action, adverse event profile, and other essential considerations regarding administering the 9vHPV vaccine, which is crucial for clinicians in delivering HPV immunization to patients effectively.", "contents": "Human Papilloma Virus Vaccine -- Continuing Education Activity. The exact mechanism of action of 9vHPV\u00a0remains unclear, as\u00a0HPV only affects humans, which poses challenges for research. However, researchers hypothesize that the vaccine operates by triggering the humoral response. This activity comprehensively examines the indications, actions, and contraindications of the 9vHPV vaccine as a crucial tool in managing and preventing HPV infection and associated diseases. Furthermore, this activity underscores the mechanism of action, adverse event profile, and other essential considerations regarding administering the 9vHPV vaccine, which is crucial for clinicians in delivering HPV immunization to patients effectively."}
{"id": "article-23033_2", "title": "Human Papilloma Virus Vaccine -- Continuing Education Activity", "content": "Objectives: Identify individuals eligible for the human papillomavirus vaccine (9vHPV) based on current guidelines, considering age, gender, and other relevant factors. Differentiate between the various human papillomavirus vaccines (HPV) available, including the bivalent, quadrivalent, and 9-valent formulations, based on their indications, dosing schedules, and target HPV types. Implement evidence-based protocols for administering the human papillomavirus vaccine, ensuring adherence to recommended dosing schedules and administration routes. Collaborate with other healthcare providers, such as pharmacists, nurses, and public health officials, to promote human papillomavirus\u00a0vaccination initiatives and ensure comprehensive vaccination coverage within the community. Access free multiple choice questions on this topic.", "contents": "Human Papilloma Virus Vaccine -- Continuing Education Activity. Objectives: Identify individuals eligible for the human papillomavirus vaccine (9vHPV) based on current guidelines, considering age, gender, and other relevant factors. Differentiate between the various human papillomavirus vaccines (HPV) available, including the bivalent, quadrivalent, and 9-valent formulations, based on their indications, dosing schedules, and target HPV types. Implement evidence-based protocols for administering the human papillomavirus vaccine, ensuring adherence to recommended dosing schedules and administration routes. Collaborate with other healthcare providers, such as pharmacists, nurses, and public health officials, to promote human papillomavirus\u00a0vaccination initiatives and ensure comprehensive vaccination coverage within the community. Access free multiple choice questions on this topic."}
{"id": "article-23033_3", "title": "Human Papilloma Virus Vaccine -- Indications", "content": "The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58.\u00a0HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization.\u00a0The exact mechanism of action of 9vHPV\u00a0remains unclear, as\u00a0HPV only affects humans, which\u00a0poses challenges for research.\u00a0However, researchers hypothesize that the vaccine operates by triggering the humoral response.", "contents": "Human Papilloma Virus Vaccine -- Indications. The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58.\u00a0HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization.\u00a0The exact mechanism of action of 9vHPV\u00a0remains unclear, as\u00a0HPV only affects humans, which\u00a0poses challenges for research.\u00a0However, researchers hypothesize that the vaccine operates by triggering the humoral response."}
{"id": "article-23033_4", "title": "Human Papilloma Virus Vaccine -- Indications -- FDA-Approved Indications", "content": "The 3 different FDA-approved vaccines designed to protect against infection from different numbers of HPV types are mentioned below. 2vHPV (bivalent vaccine): Protects against HPV types 16 and 18. Although this vaccine is unavailable in the United States, it is still used in other countries. 4vHPV (quadrivalent vaccine): Protects against HPV types 6, 11, 16, and 18. 9vHPV (9-valent vaccine): Protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.\u00a0This is the only HPV vaccine available in the United States that confers protection against these specific HPV types. The 9vHPV vaccine is routinely recommended for males and females aged 9 to 45 to prevent various diseases and dysplastic lesions caused by HPV, [1] which include the following: Anal, oropharyngeal, cervical, vulvar, vaginal, and other head-and-neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. Condyloma acuminata (genital warts) caused by HPV types 6 and 11.", "contents": "Human Papilloma Virus Vaccine -- Indications -- FDA-Approved Indications. The 3 different FDA-approved vaccines designed to protect against infection from different numbers of HPV types are mentioned below. 2vHPV (bivalent vaccine): Protects against HPV types 16 and 18. Although this vaccine is unavailable in the United States, it is still used in other countries. 4vHPV (quadrivalent vaccine): Protects against HPV types 6, 11, 16, and 18. 9vHPV (9-valent vaccine): Protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.\u00a0This is the only HPV vaccine available in the United States that confers protection against these specific HPV types. The 9vHPV vaccine is routinely recommended for males and females aged 9 to 45 to prevent various diseases and dysplastic lesions caused by HPV, [1] which include the following: Anal, oropharyngeal, cervical, vulvar, vaginal, and other head-and-neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. Condyloma acuminata (genital warts) caused by HPV types 6 and 11."}
{"id": "article-23033_5", "title": "Human Papilloma Virus Vaccine -- Indications -- FDA-Approved Indications", "content": "Cervical adenocarcinoma in situ, anal, cervical, vulvar, and vaginal intraepithelial neoplasias caused by HPV types 16, 18, 31, 33, 45, 52, and 58. Routine vaccination with\u00a09vHPV is\u00a0recommended for several patient populations, [2] which include the following: Males and females\u00a0aged 9 through 45 who have not previously received a vaccination or who did not complete the currently recommended 3-dose regimen. Men who have sex with men (MSM)\u00a0aged 26 and\u00a0older. Patients with the immunocompromised state who have no prior vaccination or who did not complete the 3-dose regimen. Victims of sexual abuse or assault. Transgender individuals/. Vaccination with 9vHPV does not replace the need for regular screening for cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers.", "contents": "Human Papilloma Virus Vaccine -- Indications -- FDA-Approved Indications. Cervical adenocarcinoma in situ, anal, cervical, vulvar, and vaginal intraepithelial neoplasias caused by HPV types 16, 18, 31, 33, 45, 52, and 58. Routine vaccination with\u00a09vHPV is\u00a0recommended for several patient populations, [2] which include the following: Males and females\u00a0aged 9 through 45 who have not previously received a vaccination or who did not complete the currently recommended 3-dose regimen. Men who have sex with men (MSM)\u00a0aged 26 and\u00a0older. Patients with the immunocompromised state who have no prior vaccination or who did not complete the 3-dose regimen. Victims of sexual abuse or assault. Transgender individuals/. Vaccination with 9vHPV does not replace the need for regular screening for cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers."}
{"id": "article-23033_6", "title": "Human Papilloma Virus Vaccine -- Mechanism of Action", "content": "The exact mechanism of action of 9vHPV is unknown. Nevertheless,\u00a0researchers believe that the vaccine works by activating the humoral response. 9vHPV is a noninfectious recombinant vaccine containing purified virus-like particles (VLPs)\u00a0obtained from the major capsid (L1) protein of HPV serotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58. The L1 proteins are separated using recombinant Saccharomyces cerevisiae and self-assembled into VLPs. Each 0.5 mL dose of the vaccine contains aluminum, sodium chloride, L-histidine, polysorbate, sodium borate, yeast protein less than 7 mcg, and water. The product does not contain preservatives or antibiotics. [3] [4]", "contents": "Human Papilloma Virus Vaccine -- Mechanism of Action. The exact mechanism of action of 9vHPV is unknown. Nevertheless,\u00a0researchers believe that the vaccine works by activating the humoral response. 9vHPV is a noninfectious recombinant vaccine containing purified virus-like particles (VLPs)\u00a0obtained from the major capsid (L1) protein of HPV serotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58. The L1 proteins are separated using recombinant Saccharomyces cerevisiae and self-assembled into VLPs. Each 0.5 mL dose of the vaccine contains aluminum, sodium chloride, L-histidine, polysorbate, sodium borate, yeast protein less than 7 mcg, and water. The product does not contain preservatives or antibiotics. [3] [4]"}
{"id": "article-23033_7", "title": "Human Papilloma Virus Vaccine -- Mechanism of Action", "content": "A 2016 immunogenicity study reports that the inactive HPV L1 VLPs in the vaccine produce neutralizing antibodies against HPV types, eliciting a strong humoral immune response to protect against the dysplastic lesions caused by HPV. The same study reported that antibody titers for 9vHPV are 10- to 100-fold more significant than those produced by natural infection. Thus, the vaccine's efficacy\u00a0is mediated via humoral response mechanisms. [5]", "contents": "Human Papilloma Virus Vaccine -- Mechanism of Action. A 2016 immunogenicity study reports that the inactive HPV L1 VLPs in the vaccine produce neutralizing antibodies against HPV types, eliciting a strong humoral immune response to protect against the dysplastic lesions caused by HPV. The same study reported that antibody titers for 9vHPV are 10- to 100-fold more significant than those produced by natural infection. Thus, the vaccine's efficacy\u00a0is mediated via humoral response mechanisms. [5]"}
{"id": "article-23033_8", "title": "Human Papilloma Virus Vaccine -- Administration -- Available Dosage Forms and Strengths", "content": "9vHPV administration is an intramuscular (IM) injection in the deltoid region or anterolateral thigh area. A single dose for adults and pediatric patients consists of a 0.5-mL suspension. 9vHPV is administered in a 2- or 3-dose schedule depending on the patient's age at initial vaccination. [6]", "contents": "Human Papilloma Virus Vaccine -- Administration -- Available Dosage Forms and Strengths. 9vHPV administration is an intramuscular (IM) injection in the deltoid region or anterolateral thigh area. A single dose for adults and pediatric patients consists of a 0.5-mL suspension. 9vHPV is administered in a 2- or 3-dose schedule depending on the patient's age at initial vaccination. [6]"}
{"id": "article-23033_9", "title": "Human Papilloma Virus Vaccine -- Administration -- Dosages", "content": "Two-dose schedule\u00a0for patients aged 9 through 14 at initial vaccination: 0, 6 to 12 months: A minimum of\u00a05 months between doses. 0, 2, 6 months: If administration of the second suspension occurs before the 5-month mark, then a third suspension should be administered\u00a04 months after the second dose, at the latest. [6] Three-dose schedule for patients aged 15 through 45 at initial vaccination according to manufacturer's labeling (may not reflect current clinical practice): 0, 2, 6 months [6]", "contents": "Human Papilloma Virus Vaccine -- Administration -- Dosages. Two-dose schedule\u00a0for patients aged 9 through 14 at initial vaccination: 0, 6 to 12 months: A minimum of\u00a05 months between doses. 0, 2, 6 months: If administration of the second suspension occurs before the 5-month mark, then a third suspension should be administered\u00a04 months after the second dose, at the latest. [6] Three-dose schedule for patients aged 15 through 45 at initial vaccination according to manufacturer's labeling (may not reflect current clinical practice): 0, 2, 6 months [6]"}
{"id": "article-23033_10", "title": "Human Papilloma Virus Vaccine -- Administration", "content": "The series can continue as previously scheduled and does not need to be restarted if the schedule is interrupted. [2] Lastly, 9vHPV can\u00a0be administered simultaneously with other routine vaccinations such as the meningococcal (groups A, C, Y, and W-135), polysaccharide diphtheria toxoid conjugate vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap).\u00a0Coadministration of 9vHPV with either of these vaccinations is well tolerated and does not interfere with\u00a0the effect; however, the recommendation is to administer in different body sites. [7] Current vaccination recommendations are based on the guidelines provided by the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP). [8]", "contents": "Human Papilloma Virus Vaccine -- Administration. The series can continue as previously scheduled and does not need to be restarted if the schedule is interrupted. [2] Lastly, 9vHPV can\u00a0be administered simultaneously with other routine vaccinations such as the meningococcal (groups A, C, Y, and W-135), polysaccharide diphtheria toxoid conjugate vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap).\u00a0Coadministration of 9vHPV with either of these vaccinations is well tolerated and does not interfere with\u00a0the effect; however, the recommendation is to administer in different body sites. [7] Current vaccination recommendations are based on the guidelines provided by the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP). [8]"}
{"id": "article-23033_11", "title": "Human Papilloma Virus Vaccine -- Administration", "content": "Routine vaccination is recommended for all individuals aged 11 to 12, with the option to begin vaccination as early as age 9. The\u00a0American Academy of Pediatrics (AAP) suggests\u00a0initiating\u00a0the HPV vaccine series for patients aged 9 through 12.\u00a0According to the AAP guidelines, parents or adolescents who avoid\u00a03 or more concomitant vaccines at age 11 or 12 may\u00a0prefer to initiate the vaccine at age 9 or 10. The American Academy of Pediatrics (AAP) policy aims to promote the introduction of the HPV vaccine at an earlier age to achieve higher vaccine initiation and completion rates. [9] ACIP also recommends vaccination for everyone through age 26 if not adequately vaccinated when younger. ACIP recommended shared clinical decision-making for patients aged 27 to 45.", "contents": "Human Papilloma Virus Vaccine -- Administration. Routine vaccination is recommended for all individuals aged 11 to 12, with the option to begin vaccination as early as age 9. The\u00a0American Academy of Pediatrics (AAP) suggests\u00a0initiating\u00a0the HPV vaccine series for patients aged 9 through 12.\u00a0According to the AAP guidelines, parents or adolescents who avoid\u00a03 or more concomitant vaccines at age 11 or 12 may\u00a0prefer to initiate the vaccine at age 9 or 10. The American Academy of Pediatrics (AAP) policy aims to promote the introduction of the HPV vaccine at an earlier age to achieve higher vaccine initiation and completion rates. [9] ACIP also recommends vaccination for everyone through age 26 if not adequately vaccinated when younger. ACIP recommended shared clinical decision-making for patients aged 27 to 45."}
{"id": "article-23033_12", "title": "Human Papilloma Virus Vaccine -- Administration -- Patients aged 9 to 15:", "content": "Two doses of the HPV vaccine are recommended for most patients. The second dose of the HPV vaccine is administered 6 to 12 months after the first dose. Adolescents who have received\u00a02 doses less than\u00a05 months apart require a third dose of the HPV vaccine.", "contents": "Human Papilloma Virus Vaccine -- Administration -- Patients aged 9 to 15:. Two doses of the HPV vaccine are recommended for most patients. The second dose of the HPV vaccine is administered 6 to 12 months after the first dose. Adolescents who have received\u00a02 doses less than\u00a05 months apart require a third dose of the HPV vaccine."}
{"id": "article-23033_13", "title": "Human Papilloma Virus Vaccine -- Administration -- Patients aged\u00a015 to 26:", "content": "Three doses of the HPV vaccine are recommended for teens and young adults who start the series at ages 15 through 26. The recommended three-dose schedule is 0, 1\u00a0to 2, and 6 months. Three doses are recommended for a patient with immunocompromised conditions (eg, HIV infection, immunosuppressive therapy)", "contents": "Human Papilloma Virus Vaccine -- Administration -- Patients aged\u00a015 to 26:. Three doses of the HPV vaccine are recommended for teens and young adults who start the series at ages 15 through 26. The recommended three-dose schedule is 0, 1\u00a0to 2, and 6 months. Three doses are recommended for a patient with immunocompromised conditions (eg, HIV infection, immunosuppressive therapy)"}
{"id": "article-23033_14", "title": "Human Papilloma Virus Vaccine -- Administration -- Patients aged\u00a027 to 45:", "content": "ACIP (2019) recommended shared clinical decision-making for patients aged 27 to 45, as most adults in this age group have minimal benefits from vaccination. Individuals who are not already immunized to HPV (eg, a previously unvaccinated person who has never had sex) and the person at risk for acquiring a newer HPV infection soon (eg, who plans to have sex with a new partner) might get benefit from vaccination. [10] HPV vaccines are not licensed in adults aged 45 and older.", "contents": "Human Papilloma Virus Vaccine -- Administration -- Patients aged\u00a027 to 45:. ACIP (2019) recommended shared clinical decision-making for patients aged 27 to 45, as most adults in this age group have minimal benefits from vaccination. Individuals who are not already immunized to HPV (eg, a previously unvaccinated person who has never had sex) and the person at risk for acquiring a newer HPV infection soon (eg, who plans to have sex with a new partner) might get benefit from vaccination. [10] HPV vaccines are not licensed in adults aged 45 and older."}
{"id": "article-23033_15", "title": "Human Papilloma Virus Vaccine -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: The manufacturer's product labeling provides no information regarding dose adjustment in patients with hepatic impairment. Renal impairment: The manufacturer's product labeling provides no information regarding dose adjustment in patients with\u00a0renal impairment.", "contents": "Human Papilloma Virus Vaccine -- Administration -- Specific Patient Populations. Hepatic impairment: The manufacturer's product labeling provides no information regarding dose adjustment in patients with hepatic impairment. Renal impairment: The manufacturer's product labeling provides no information regarding dose adjustment in patients with\u00a0renal impairment."}
{"id": "article-23033_16", "title": "Human Papilloma Virus Vaccine -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: According to the CDC and the American College of Obstetricians and Gynecologists\u00a0(ACOG), the\u00a0HPV vaccine is not recommended during pregnancy. However, if the vaccine is accidentally administered to a pregnant woman, the patient should be informed that available safety data are reassuring. In addition, if a vaccine series is initiated and a patient becomes pregnant, the clinician should postpone the vaccine series until\u00a0the pregnancy is completed. [11]", "contents": "Human Papilloma Virus Vaccine -- Administration -- Specific Patient Populations. Pregnancy considerations: According to the CDC and the American College of Obstetricians and Gynecologists\u00a0(ACOG), the\u00a0HPV vaccine is not recommended during pregnancy. However, if the vaccine is accidentally administered to a pregnant woman, the patient should be informed that available safety data are reassuring. In addition, if a vaccine series is initiated and a patient becomes pregnant, the clinician should postpone the vaccine series until\u00a0the pregnancy is completed. [11]"}
{"id": "article-23033_17", "title": "Human Papilloma Virus Vaccine -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: According to the CDC, vaccines given to a nursing mother do not impact breastfeeding safety for mothers or infants. For instance, a slightly higher percentage of breastfed infants with the active quadrivalent\u00a0HPV vaccine had pneumonia 30 days after maternal vaccination. Still, these effects were not attributable to the vaccine. Maternal vaccination is not a contraindication to breastfeeding; clinicians may administer the HPV to breastfeeding patients. [12] According to ACOG 2020 guidelines, the\u00a0HPV vaccine should be administered to breastfeeding women aged 26 and younger who have not been previously vaccinated. [11]", "contents": "Human Papilloma Virus Vaccine -- Administration -- Specific Patient Populations. Breastfeeding considerations: According to the CDC, vaccines given to a nursing mother do not impact breastfeeding safety for mothers or infants. For instance, a slightly higher percentage of breastfed infants with the active quadrivalent\u00a0HPV vaccine had pneumonia 30 days after maternal vaccination. Still, these effects were not attributable to the vaccine. Maternal vaccination is not a contraindication to breastfeeding; clinicians may administer the HPV to breastfeeding patients. [12] According to ACOG 2020 guidelines, the\u00a0HPV vaccine should be administered to breastfeeding women aged 26 and younger who have not been previously vaccinated. [11]"}
{"id": "article-23033_18", "title": "Human Papilloma Virus Vaccine -- Adverse Effects", "content": "The most common adverse effects recorded\u00a0with 9vHPV are injection-site events, systemic events, and syncope. [13] [14] Injection-site events were recorded within\u00a05 days after vaccination, including pain, swelling, erythema, and tenderness. [14] [15] Systemic events were recorded within\u00a015 days\u00a0following vaccination, including headaches, pyrexia, fatigue, and nausea. [15] Syncope after administration of 9vHPV\u00a0is reported, occurring post-administration of the vaccine and posing a significant risk of severe secondary injury to patients.", "contents": "Human Papilloma Virus Vaccine -- Adverse Effects. The most common adverse effects recorded\u00a0with 9vHPV are injection-site events, systemic events, and syncope. [13] [14] Injection-site events were recorded within\u00a05 days after vaccination, including pain, swelling, erythema, and tenderness. [14] [15] Systemic events were recorded within\u00a015 days\u00a0following vaccination, including headaches, pyrexia, fatigue, and nausea. [15] Syncope after administration of 9vHPV\u00a0is reported, occurring post-administration of the vaccine and posing a significant risk of severe secondary injury to patients."}
{"id": "article-23033_19", "title": "Human Papilloma Virus Vaccine -- Adverse Effects", "content": "A 2016 study concluded that incidences of adverse effects were comparable\u00a0in all age groups. [6] This study also concluded that the safety profile of 9vHPV is comparable to its quadrivalent counterpart, 4vHPV. Injection site effects\u00a0are common with\u00a09vHPV, given more HPV virus-like antigens and aluminum hydroxyphosphate sulfate adjuvants, which help potentiate the immunological response. [16]", "contents": "Human Papilloma Virus Vaccine -- Adverse Effects. A 2016 study concluded that incidences of adverse effects were comparable\u00a0in all age groups. [6] This study also concluded that the safety profile of 9vHPV is comparable to its quadrivalent counterpart, 4vHPV. Injection site effects\u00a0are common with\u00a09vHPV, given more HPV virus-like antigens and aluminum hydroxyphosphate sulfate adjuvants, which help potentiate the immunological response. [16]"}
{"id": "article-23033_20", "title": "Human Papilloma Virus Vaccine -- Adverse Effects", "content": "Postmarketing surveillance of the\u00a0HPV\u00a0vaccine has identified\u00a0multiple adverse events following immunization, such as abdominal pain, syncope, dizziness,\u00a0loss of consciousness, alopecia, amenorrhea, anemia, dyskinesia, migraine,\u00a0pallor, and seizures. [17]", "contents": "Human Papilloma Virus Vaccine -- Adverse Effects. Postmarketing surveillance of the\u00a0HPV\u00a0vaccine has identified\u00a0multiple adverse events following immunization, such as abdominal pain, syncope, dizziness,\u00a0loss of consciousness, alopecia, amenorrhea, anemia, dyskinesia, migraine,\u00a0pallor, and seizures. [17]"}
{"id": "article-23033_21", "title": "Human Papilloma Virus Vaccine -- Adverse Effects", "content": "According to a comprehensive surveillance study conducted over\u00a05 years involving the administration of more than 1.8 million doses of the 9vHPV vaccine to individuals aged 9\u00a0to 26, no statistically significant increases in the risk of Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy, or stroke were observed following vaccination with the 9vHPV vaccine. These longer-term findings\u00a0endorse the safety of the 9vHPV vaccine. [18]", "contents": "Human Papilloma Virus Vaccine -- Adverse Effects. According to a comprehensive surveillance study conducted over\u00a05 years involving the administration of more than 1.8 million doses of the 9vHPV vaccine to individuals aged 9\u00a0to 26, no statistically significant increases in the risk of Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy, or stroke were observed following vaccination with the 9vHPV vaccine. These longer-term findings\u00a0endorse the safety of the 9vHPV vaccine. [18]"}
{"id": "article-23033_22", "title": "Human Papilloma Virus Vaccine -- Adverse Effects -- Drug-Vaccine Interactions", "content": "Immunosuppressive therapies, such as irradiation, alkylating agents, antimetabolites, cytotoxic medications, and corticosteroids, attenuate immune responses to the HPV vaccine.", "contents": "Human Papilloma Virus Vaccine -- Adverse Effects -- Drug-Vaccine Interactions. Immunosuppressive therapies, such as irradiation, alkylating agents, antimetabolites, cytotoxic medications, and corticosteroids, attenuate immune responses to the HPV vaccine."}
{"id": "article-23033_23", "title": "Human Papilloma Virus Vaccine -- Contraindications", "content": "Vaccine-related anaphylactic reactions are uncommon; however, anaphylaxis to a known vaccine ingredient is an absolute contraindication to immunization. [13] As a result, 9vHPV is contraindicated in individuals with a history of hypersensitivity reactions to yeast since 9vHPV is a recombinant vaccine expressed in S cerevisiae (brewer\u2019s yeast). [2]", "contents": "Human Papilloma Virus Vaccine -- Contraindications. Vaccine-related anaphylactic reactions are uncommon; however, anaphylaxis to a known vaccine ingredient is an absolute contraindication to immunization. [13] As a result, 9vHPV is contraindicated in individuals with a history of hypersensitivity reactions to yeast since 9vHPV is a recombinant vaccine expressed in S cerevisiae (brewer\u2019s yeast). [2]"}
{"id": "article-23033_24", "title": "Human Papilloma Virus Vaccine -- Contraindications", "content": "Contraindications include persons with previous hypersensitivity reactions to a dose of 9vHPV or\u00a04vHPV (quadrivalent vaccine). [2] According to the CDC, moderate or severe acute illness is a precaution to vaccination, and clinicians should postpone vaccination until symptoms of the critical illness improve.", "contents": "Human Papilloma Virus Vaccine -- Contraindications. Contraindications include persons with previous hypersensitivity reactions to a dose of 9vHPV or\u00a04vHPV (quadrivalent vaccine). [2] According to the CDC, moderate or severe acute illness is a precaution to vaccination, and clinicians should postpone vaccination until symptoms of the critical illness improve."}
{"id": "article-23033_25", "title": "Human Papilloma Virus Vaccine -- Contraindications", "content": "The safety of 9vHPV\u00a0has not been studied in pregnant human subjects; thus, 9vHPV is not currently recommended in pregnancy. A 2018 animal study assessed the general, reproductive, and developmental toxicity of 9vHPV in Sprague-Dawley rats. The study followed a 3-month repeat-dose toxicity study on rats, reporting no effects on the reproductive ability of rats, no effects on offspring development, no vaccine-related fetal abnormalities, and no effect on male rat fertility. [19]", "contents": "Human Papilloma Virus Vaccine -- Contraindications. The safety of 9vHPV\u00a0has not been studied in pregnant human subjects; thus, 9vHPV is not currently recommended in pregnancy. A 2018 animal study assessed the general, reproductive, and developmental toxicity of 9vHPV in Sprague-Dawley rats. The study followed a 3-month repeat-dose toxicity study on rats, reporting no effects on the reproductive ability of rats, no effects on offspring development, no vaccine-related fetal abnormalities, and no effect on male rat fertility. [19]"}
{"id": "article-23033_26", "title": "Human Papilloma Virus Vaccine -- Contraindications", "content": "These results add to the available data that 9vHPV does not increase the risk of adverse pregnancy outcomes in rats; however, more studies need to evaluate the safety profile in pregnant human subjects. Currently, standard protocol dictates that if a\u00a0patient is pregnant, the vaccination series should be halted and resumed after pregnancy. [20]", "contents": "Human Papilloma Virus Vaccine -- Contraindications. These results add to the available data that 9vHPV does not increase the risk of adverse pregnancy outcomes in rats; however, more studies need to evaluate the safety profile in pregnant human subjects. Currently, standard protocol dictates that if a\u00a0patient is pregnant, the vaccination series should be halted and resumed after pregnancy. [20]"}
{"id": "article-23033_27", "title": "Human Papilloma Virus Vaccine -- Monitoring", "content": "Syncope, occasionally accompanied by tonic-clonic movements and other seizure-like activity,\u00a0is documented as a potential adverse effect following HPV vaccination. Patients should receive monitoring for syncopal events to prevent severe secondary injury to the patient.", "contents": "Human Papilloma Virus Vaccine -- Monitoring. Syncope, occasionally accompanied by tonic-clonic movements and other seizure-like activity,\u00a0is documented as a potential adverse effect following HPV vaccination. Patients should receive monitoring for syncopal events to prevent severe secondary injury to the patient."}
{"id": "article-23033_28", "title": "Human Papilloma Virus Vaccine -- Monitoring", "content": "Clinicians\u00a0should monitor patients for presyncope signs and symptoms for 15 minutes when administering 9vHPV. Additionally, standard operating procedures should be in place to avoid severe secondary injuries resulting from the patient's collapse; these include keeping the patient in a Trendelenburg or supine position to maintain adequate cerebral perfusion. Patients should\u00a0be monitored for acute onset of signs and symptoms of anaphylactic reactions such as hypotension, tachycardia, urticaria, and respiratory compromise. [21]", "contents": "Human Papilloma Virus Vaccine -- Monitoring. Clinicians\u00a0should monitor patients for presyncope signs and symptoms for 15 minutes when administering 9vHPV. Additionally, standard operating procedures should be in place to avoid severe secondary injuries resulting from the patient's collapse; these include keeping the patient in a Trendelenburg or supine position to maintain adequate cerebral perfusion. Patients should\u00a0be monitored for acute onset of signs and symptoms of anaphylactic reactions such as hypotension, tachycardia, urticaria, and respiratory compromise. [21]"}
{"id": "article-23033_29", "title": "Human Papilloma Virus Vaccine -- Toxicity", "content": "9vHPV is a generally well-tolerated vaccine with a\u00a0robust safety profile. The most common adverse effects are minor issues such as injection-site pain, swelling, erythema, and tenderness. [14] Minor systemic effects have been reported, such as headaches, pyrexia, fatigue, and nausea. [15]", "contents": "Human Papilloma Virus Vaccine -- Toxicity. 9vHPV is a generally well-tolerated vaccine with a\u00a0robust safety profile. The most common adverse effects are minor issues such as injection-site pain, swelling, erythema, and tenderness. [14] Minor systemic effects have been reported, such as headaches, pyrexia, fatigue, and nausea. [15]"}
{"id": "article-23033_30", "title": "Human Papilloma Virus Vaccine -- Toxicity", "content": "Toxic effects are attributable to anaphylaxis and hypersensitivity reactions. In the case of an anaphylactic reaction, clinicians should immediately administer 1.0 mg/mL of epinephrine via the IM route in the anterolateral vastus lateralis muscle. Administration of IM epinephrine should be repeated every 5 to 15 minutes until the desired response is achieved. [22]", "contents": "Human Papilloma Virus Vaccine -- Toxicity. Toxic effects are attributable to anaphylaxis and hypersensitivity reactions. In the case of an anaphylactic reaction, clinicians should immediately administer 1.0 mg/mL of epinephrine via the IM route in the anterolateral vastus lateralis muscle. Administration of IM epinephrine should be repeated every 5 to 15 minutes until the desired response is achieved. [22]"}
{"id": "article-23033_31", "title": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes", "content": "According to the 2019 ACIP report,\u00a0HPV is responsible for an estimated 33,700 cancer cases annually in the United States. This includes 12,900 cases of oropharyngeal cancers among both men and women, 10,800 cases of cervical cancer among women, and 6,000 cases of anal cancer among both men and women. Although vaginal, vulvar, and penile cancers are relatively less frequent, they are also associated with HPV infection. [8]", "contents": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes. According to the 2019 ACIP report,\u00a0HPV is responsible for an estimated 33,700 cancer cases annually in the United States. This includes 12,900 cases of oropharyngeal cancers among both men and women, 10,800 cases of cervical cancer among women, and 6,000 cases of anal cancer among both men and women. Although vaginal, vulvar, and penile cancers are relatively less frequent, they are also associated with HPV infection. [8]"}
{"id": "article-23033_32", "title": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes", "content": "Clinicians should recognize that\u00a0the burden of HPV-related mortality is significantly greater than the combined mortality caused by tetanus, diphtheria, pertussis, and meningococcal disease. [9] To support widespread vaccination efforts and increase the global prevention of diseases and dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, clinicians must increase patient awareness during wellness visits\u00a0regarding the importance of HPV vaccination.\u00a0Interprofessional team members should also educate their patients on the different cancers and avoidable precancerous lesions when immunized with 9vHPV. Patients must be urged to complete the recommended three-dose sequence of 9vHPV.", "contents": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes. Clinicians should recognize that\u00a0the burden of HPV-related mortality is significantly greater than the combined mortality caused by tetanus, diphtheria, pertussis, and meningococcal disease. [9] To support widespread vaccination efforts and increase the global prevention of diseases and dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, clinicians must increase patient awareness during wellness visits\u00a0regarding the importance of HPV vaccination.\u00a0Interprofessional team members should also educate their patients on the different cancers and avoidable precancerous lesions when immunized with 9vHPV. Patients must be urged to complete the recommended three-dose sequence of 9vHPV."}
{"id": "article-23033_33", "title": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes", "content": "Clinicians can increase vaccine\u00a0compliance\u00a0by scheduling follow-up visits in person. Further, clinics, pharmacies, and hospitals should implement standard operating procedures to prevent severe injury, such as safe vaccine administration spaces.", "contents": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes. Clinicians can increase vaccine\u00a0compliance\u00a0by scheduling follow-up visits in person. Further, clinics, pharmacies, and hospitals should implement standard operating procedures to prevent severe injury, such as safe vaccine administration spaces."}
{"id": "article-23033_34", "title": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes", "content": "Interventions that include healthcare education, tailored systems changes, feedback, and early initiation of the HPV vaccine may improve patient adherence and completion of vaccination schedules. [23]  Moreover, healthcare professionals should be aware of and attentive to the acute onset of symptoms of an anaphylactic reaction.", "contents": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes. Interventions that include healthcare education, tailored systems changes, feedback, and early initiation of the HPV vaccine may improve patient adherence and completion of vaccination schedules. [23]  Moreover, healthcare professionals should be aware of and attentive to the acute onset of symptoms of an anaphylactic reaction."}
{"id": "article-23033_35", "title": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes", "content": "All healthcare team members should receive training in the administration of epinephrine auto-injectors. Clinicians should\u00a0prescribe the HPV vaccine according to the latest ACIP and CDC recommendations. Nurses should administer and monitor for adverse reactions. Pharmacists should report adverse events following immunization by the Vaccine Adverse Event Reporting System (VAERS), which would enhance patient safety. [24] Interprofessional collaboration between clinicians and pharmacists facilitates improved outcomes with reduced adverse reactions, along with higher vaccination rates and increased public awareness regarding the significance of the 9vHPV vaccination.", "contents": "Human Papilloma Virus Vaccine -- Enhancing Healthcare Team Outcomes. All healthcare team members should receive training in the administration of epinephrine auto-injectors. Clinicians should\u00a0prescribe the HPV vaccine according to the latest ACIP and CDC recommendations. Nurses should administer and monitor for adverse reactions. Pharmacists should report adverse events following immunization by the Vaccine Adverse Event Reporting System (VAERS), which would enhance patient safety. [24] Interprofessional collaboration between clinicians and pharmacists facilitates improved outcomes with reduced adverse reactions, along with higher vaccination rates and increased public awareness regarding the significance of the 9vHPV vaccination."}
{"id": "article-23033_36", "title": "Human Papilloma Virus Vaccine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Human Papilloma Virus Vaccine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}